Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran ). part I. absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers

This publication has 8 references indexed in Scilit:

• A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group
  Human Reproduction, 1998
• Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers
  Human Reproduction, 1998
• Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray
  Fertility and Sterility, 1997
• Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
  Fertility and Sterility, 1995
• GONADOTROPIN-RELEASING HORMONE AND ITS ANALOGS
  Annual Review of Medicine, 1994
• Radioimmunoassay of Ganirelix in Plasma or Serum
  Journal of Immunoassay, 1993
• Mode of Suppression of Pituitary and Gonadal Function After Acute or Prolonged Administration of a Luteinizing Hormone-Releasing Hormone Antagonist in Normal Men*
  Journal of Clinical Endocrinology & Metabolism, 1989
• Antagonistic Analogs of Luteinizing Hormone-Releasing Hormone Are Mast Cell Secretagogues
  International Archives of Allergy and Immunology, 1986